Another biomarker analysis from the DESTINY-CRC01, including patients with advanced colorectal cancer, showed that T-DXd efficacy is correlated to higher baseline HER2 levels in both tissue (IHC/ISH) and peripheral blood (copy number of ERBB2 in plasma and circulating HER2-extra cellular domain). Here, ERBB2 is linked to colorectal cancer.